Nasopharyngeal Carcinoma Clinical Trials (April 2026): 142 Recruiting Interventional Studies

Last updated: April 18, 2026

Current Clinical Trial Landscape

Active research areas in 2026:

Immunotherapy + chemoradiotherapy for locally advanced disease (57 Phase 3 trials)
EBV DNA-guided treatment stratification (reduce treatment for good responders)
Proton therapy vs photon IMRT (2 Phase 3 trials)
EBV-targeted CAR-T/TCR-T cell therapy

Standard of care: GP (gemcitabine + cisplatin) induction → concurrent chemoRT → ± adjuvant therapy. Immunotherapy (PD-1 inhibitors) increasingly standard in recurrent/metastatic setting.

Recruiting Trials by Treatment Stage

First-Line Locally Advanced (Curative Intent)

Standard treatment is GP induction + concurrent chemoRT. These trials test immunotherapy additions, radiation optimization, or EBV-guided de-escalation:

Immunotherapy + standard treatment:
- NCT06712888 - Toripalimab vs Placebo + GP induction (Phase 3)
- NCT04453826 - Camrelizumab + chemoRT vs chemoRT alone (Phase 3)
- NCT06749899 - QL1706 (PD-1/CTLA-4 bispecific) + chemoRT (Phase 3)
- NCT07154069 - Adaptive immunotherapy for NPC (Phase 3)
- NCT07524413 - Becotatug vedotin (MRG003) + PD-1 + chemoRT in high-risk LA-NPC (Phase 3)
- NCT07459296 - Becotatug vedotin + sintilimab in locoregionally advanced NPC (Phase 3)
Intensified for high-risk (detectable EBV DNA):
- NCT05772208 - Camrelizumab + Nimotuzumab for EBV+ after 1 cycle GP (Phase 3)
- NCT06437627 - TPC + Apatinib + Camrelizumab for high-risk (Phase 3)
- NCT07496190 - Becotatug vedotin for LA-NPC with suboptimal response to induction (Phase 2)
De-escalation for good responders (undetectable EBV DNA):
- NCT05674305 - RT alone vs concurrent chemoRT (Phase 3)
- NCT06092957 - Reduced-dose RT ± CCT for CR after induction (Phase 3)
- NCT04448522 - Reduced vs conventional dose IMRT (Phase 3)
Proton therapy:
- NCT07340515 - Proton vs Photon IMRT (Phase 3)
- NCT07000643 - Proton vs Photon therapy (Phase 3, non-inferiority)

Recurrent or Metastatic

Immunotherapy + chemotherapy is becoming standard. These trials test new combinations or targets:

First-line R/M:
- NCT05854849 - Gemcitabine + Camrelizumab + Apatinib vs GP + Cisplatin (Phase 3)
- NCT06176301 - Tislelizumab + GX vs GP (Phase 3)
- NCT06382780 - Tislelizumab + GP or TPC for bone metastasis (Phase 3)
Second-line+ (after immunotherapy):
- NCT06976190 - MRG003 (ADC) + Pucotenlimab vs chemo (Phase 3)
- NCT06629597 - YL201 vs docetaxel/capecitabine (Phase 3)
- NCT06259721 - Anti-PD1 + Nimotuzumab + Capecitabine (platinum-resistant)
- NCT06676722 - SBRT + Nimotuzumab + Tislelizumab (oligoprogression after IO)
Oligometastatic:
- NCT04944914 - Camrelizumab + SBRT vs Camrelizumab alone (Phase 3)
- NCT07235319 - Immediate vs salvage locoregional RT (Phase 3)

Locoregional Recurrence

For disease recurring in the nasopharynx/neck after prior treatment:

Re-irradiation:
- NCT05340491 - ChemoRT + Toripalimab vs ChemoRT alone (Phase 3)
- NCT04453813 - Toripalimab + concurrent chemoRT (Phase 3)
- NCT03907826 - PD-1 antibody + chemoRT for recurrent T3/T4 (Phase 3)
Surgery + adjuvant:
- NCT04778956 - Toripalimab + surgery vs surgery alone (Phase 3)
- NCT05877872 - Reduced-target vs full-target resection (Phase 3)
- NCT06912711 - Toripalimab + Nimotuzumab neoadjuvant/adjuvant

Novel Approaches

EBV-targeted cellular therapy:
- NCT05587543 - EBV CAR-T/TCR-T cells for NPC
ADC (antibody-drug conjugate):
- NCT06976190 - MRG003 (EGFR-ADC) + Pucotenlimab (Phase 3)
- NCT06475300 - BL-B01D1 (EGFR×HER3 bispecific ADC) + PD-1
- NCT06839066 - HLX43 (PD-L1 ADC) for R/M NPC (Phase 2)
Bispecific antibody:
- NCT06749899 - QL1706 (PD-1/CTLA-4) + chemoRT (Phase 3)

Showing selected notable trials. View all 142 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find NPC clinical trials I'm eligible for?

Paste your medical summary into ClinTrialFinder and get AI-matched NPC trials in minutes. The tool considers your EBV status, cancer stage, prior treatments, and whether you have locally advanced or metastatic disease.

What nasopharyngeal carcinoma trials are currently recruiting?

There are 142 recruiting interventional trials for nasopharyngeal carcinoma including immunotherapy (PD-1/PD-L1 inhibitors), EBV-targeted therapies, radiation optimization trials, and combination treatments.

Find NPC Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials